This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pulmonary Fibrosis Foundation To Fund Further Therapeutic Evaluation Studies For Compugen-Discovered Drug Candidate

Stocks in this article: CGEN

Compugen Ltd. (NASDAQ: CGEN) and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis (IPF), a devastating disease with no current effective treatment and which is estimated to affect more than five million people worldwide.

CGEN-25009, a novel peptide agonist of the relaxin receptor, was discovered during the validation stage of Compugen’s GPCR Peptide Ligand Discovery Platform. As already announced by Compugen, studies conducted by Professor Daniele Bani, a world expert in the field of relaxin and fibrotic diseases from the University of Florence (Italy), previously demonstrated the therapeutic effect of CGEN-25009, leading to robust reduction of the fibrotic tissue in the lungs of mice induced with pulmonary fibrosis. The results of Professor Bani's studies conducted with CGEN-25009 were recently published in the Journal of Pharmacology and Experimental Therapeutics.

Substantial worldwide research efforts have recently demonstrated that the natural peptide hormone relaxin, in addition to its historical role as the “pregnancy hormone,” is multi-functional and affects a range of tissues. Known to activate the LGR7(RXFP1) G protein-coupled receptor, the diverse and vital roles of relaxin include protective cardiovascular and anti-fibrotic activity, and roles in reproductive health, wound healing, fertility and ageing.

“Our experiments are designed to further establish the anti-fibrotic properties of CGEN-25009 in multiple animal models of fibrosis, to elucidate the mechanism of CGEN-25009's anti-fibrotic effects, and to prioritize potential biomarkers for the study of CGEN-25009 in patients with idiopathic pulmonary fibrosis,” said study leader Dr. Daniel Kass, Assistant Director for Novel Therapeutics and Translational Research at the Simmons Center.

“It is exciting that patient advocacy groups such as the Pulmonary Fibrosis Foundation are spearheading the effort to enhance collaborations between industry and academia in finding the cure for IPF,” said co-investigator and Simmons Center director Dr. Naftali Kaminski, Professor of Medicine, Pathology, Human Genetics and Computational Biology. “This effort could generate significant insights that will potentially change our understanding and management of lung fibrosis.”

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs